glp-1 insurance coverage GLP-1s and The Payer Predicament Does health insurance cover GLP-1

Reports of severe delayed gastric emptying (stomach paralysis) remain a clinical concern

Today's findings strongly signal that a digital-first, personalized experience is precisely what helps people stick to their treatment plans to drive lasting outcomes." Download the full white paper here

Currently, clinical trials are underway to evaluate the safety and efficacy of tirzepatide in patients with heart failure

Important factors affecting GLP-1 market demand and take-up include: The need for better long-term data on the safety and efficacy of use for the designated indications The rapidly expanding list of potential new indications for the drugs, including chronic kidney disease, broader cardiovascular risk reduction, metabolic liver disease, and Alzheimer's disease The number of similar drugs in the development pipeline Price point versus competition, which affects affordability and insurance coverage Marketing efforts of the manufacturers, supply and distribution constraints

Distributed throughout the skin, intestine, kidneys, liver, and other organs, DPP-4 not only cleaves incretins, but also other proteins with proline (P) or alanine (A) residues as the second amino acid (Wani et al., 2008)